Urinary Tract Infections
Conditions
Brief summary
This is a non-randomized, open-label, one-treatment, one group study in participants with complicated urinary tract infection (cUTI) including pyelonephritis to characterize the pharmacokinetics of RO7079901 co-administered with meropenem.
Interventions
DRUGRO7079901
Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.
DRUGMeropenem
Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.
Sponsors
Hoffmann-La Roche
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Requiring hospitalization for IV antibacterial therapy for the treatment of presumed/confirmed cUTI (including pyelonephritis) * Clinical signs and/or symptoms of pyelonephritis or a cUTI * Urine culture taken within the 48 hours (hr) period immediately preceding the first dose of study drug contains greater than (\>)1x10\^5 colony forming units (CFU) per milliliter (CFU/mL) of a gram negative organism * Negative urine pregnancy test result confirmed by a blood test * Agreement to remain abstinent or use a contraceptive method
Exclusion criteria
* Has a concomitant infection requiring antibacterial therapy, in addition to study drug * Confirmed fungal urinary tract infection * Moderate or severe renal impairment, or end-stage renal disease requiring renal replacement therapy or a recipient of a renal transplant * Documented presence of immunodeficiency, or a severely immunocompromised condition or use of systemic immunosuppressant therapy * Any rapidly progressing disease or immediately life-threatening illness, or other terminal illness or condition with high risk of mortality meaning that the participant is considered, in the opinion of the Investigator, unlikely to survive the study period * Urinary tract surgery or clinically significant urogenital trauma in the one week immediately preceding study entry * Urinary tract infection (UTI) symptoms potentially attributable to another process (sexually transmitted infections or prostatitis) * Suspected or confirmed perinephric or intra renal abscess * Complete obstruction of any portion of the urinary tract, or a permanent urinary diversion * History of epilepsy, brain lesions or other significant neurological disorders * Use of probenecid within the 7 days before enrollment * Known history of clinically significant hypersensitivity or severe allergic reaction to meropenem or any other antibiotic * Any other ongoing condition or disease, or clinically significant abnormalities in laboratory test results that the investigator considers would render the participant unsuitable for the study * Women who are pregnant, planning to become pregnant, or lactating * Participation in a clinical study of an investigational drug or device within one month prior to enrollment * Prior enrollment in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Steady State Volume of Distribution (Vss) of RO7079901 | Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7 |
| Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (AUC0-tau) of RO7079901 | Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7 |
| Total Clearance (CL) of RO7079901 | Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7 |
| Renal Clearance (CLr) of RO7079901 | Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected) |
| Maximum Observed Plasma Concentration (Cmax) of RO7079901 | Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7 |
| Cumulative Amount Excreted in Urine Over the Dosing Interval (Ae) of RO7079901 | Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected) |
| Fraction Excreted into the Urine (Fe) of RO7079901 | Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected) |
| Time of Maximum Observed Plasma Concentration (Tmax) of RO7079901 | Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7 |
Secondary
| Measure | Time frame |
|---|---|
| AUC0-tau of Meropenem | Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7 |
| CL of Meropenem | Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7 |
| CLr of Meropenem | Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected) |
| Cmax of Meropenem | Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7 |
| Ae of Meropenem | Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected) |
| Fe of Meropenem | Days 1 and 3 (all urine passed in the 8-hour period after morning dose will be collected) |
| Tmax of Meropenem | Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7 |
| Vss of Meropenem | Pre-dose (0 hr), 1.5 hr (end of infusion [infusion duration=1.5 hr]), 3, 4.5, 6, 8 hr post dose on Days 1, 3; pre-dose (0 hr), 1.5 and 8 hr post dose on Days 5 and 7 |
Countries
Hungary, Latvia, Poland, Serbia, United States
Outcome results
None listed